QuidelOrtho (QDEL) | Financial Analysis & Statements
QuidelOrtho Corporation Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
723.6M
Gross Profit
320.4M
44.28%
Operating Income
-37.3M
-5.15%
Net Income
-130.7M
-18.06%
EPS (Diluted)
$-1.92
Balance Sheet Metrics
Total Assets
5.8B
Total Liabilities
3.8B
Shareholders Equity
1.9B
Debt to Equity
2.00
Cash Flow Metrics
Operating Cash Flow
124.1M
Free Cash Flow
86.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
QuidelOrtho Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.7B | 2.8B | 3.0B | 3.3B | 1.7B |
| Cost of Goods Sold | 1.5B | 1.5B | 1.5B | 1.3B | 420.3M |
| Gross Profit | 1.3B | 1.3B | 1.5B | 1.9B | 1.3B |
| Gross Margin % | 46.7% | 46.2% | 49.8% | 59.3% | 75.3% |
| Operating Expenses | |||||
| Research & Development | 186.2M | 218.7M | 246.8M | 190.5M | 95.7M |
| Selling, General & Administrative | 746.3M | 766.8M | 763.2M | 621.0M | 239.6M |
| Other Operating Expenses | 97.7M | 51.8M | 27.1M | 12.3M | - |
| Total Operating Expenses | 1.0B | 1.0B | 1.0B | 823.8M | 335.3M |
| Operating Income | 54.8M | 45.8M | 252.5M | 979.7M | 915.6M |
| Operating Margin % | 2.0% | 1.6% | 8.4% | 30.0% | 53.9% |
| Non-Operating Items | |||||
| Interest Income | 2.2M | 2.6M | 5.5M | 1.3M | 300.0K |
| Interest Expense | 183.1M | 188.3M | 178.9M | 74.5M | 300.0K |
| Other Non-Operating Income | -976.9M | -2.0B | -104.9M | -168.5M | -14.9M |
| Pre-tax Income | -1.1B | -2.1B | -29.1M | 735.9M | 900.3M |
| Income Tax | 24.1M | -79.5M | -19.0M | 187.2M | 196.1M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 25.4% | 21.8% |
| Net Income | -1.1B | -2.1B | -10.1M | 548.7M | 704.2M |
| Net Margin % | -41.5% | -73.7% | -0.3% | 16.8% | 41.5% |
| Key Metrics | |||||
| EBITDA | 488.5M | 491.5M | 691.3M | 1.3B | 968.3M |
| EPS (Basic) | - | $-30.16 | $-0.15 | $9.66 | $16.74 |
| EPS (Diluted) | - | $-30.16 | $-0.15 | $9.56 | $16.43 |
| Basic Shares Outstanding | - | 67200000 | 66800000 | 56800000 | 42078000 |
| Diluted Shares Outstanding | - | 67200000 | 66800000 | 56800000 | 42078000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
QuidelOrtho Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 169.8M | 98.3M | 118.9M | 292.9M | 802.8M |
| Short-term Investments | - | 0 | 48.4M | 52.1M | 25.7M |
| Accounts Receivable | 417.0M | 282.4M | 303.3M | 453.9M | 378.0M |
| Inventory | 577.6M | 533.7M | 577.8M | 524.1M | 198.8M |
| Other Current Assets | 28.2M | 1.1M | 3.1M | 900.0K | 4.5M |
| Total Current Assets | 1.4B | 1.2B | 1.3B | 1.6B | 1.4B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.1B | 909.3M | 169.6M | 181.0M | 127.6M |
| Goodwill | 2.6B | 4.0B | 7.9B | 8.1B | 772.7M |
| Intangible Assets | 2.6B | 2.7B | 2.9B | 3.1B | 98.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 244.4M | 270.7M | 205.5M | 139.1M | 39.7M |
| Total Non-Current Assets | 4.3B | 5.2B | 7.3B | 7.3B | 990.1M |
| Total Assets | 5.8B | 6.4B | 8.6B | 8.9B | 2.4B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 279.4M | 246.0M | 294.8M | 283.3M | 101.5M |
| Short-term Debt | 207.6M | 372.9M | 166.5M | 231.9M | 10.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 164.3M | 96.8M | 127.8M | 117.1M | 23.6M |
| Total Current Liabilities | 966.1M | 998.8M | 833.8M | 1.0B | 323.5M |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.6B | 2.3B | 2.4B | 2.6B | 129.0M |
| Deferred Tax Liabilities | 90.0M | 76.5M | 192.2M | 213.2M | 0 |
| Other Non-Current Liabilities | 166.4M | 55.3M | 83.6M | 83.8M | 48.5M |
| Total Non-Current Liabilities | 2.9B | 2.4B | 2.7B | 2.9B | 177.5M |
| Total Liabilities | 3.8B | 3.4B | 3.6B | 3.9B | 501.0M |
| Equity | |||||
| Common Stock | 100.0K | 100.0K | 100.0K | 0 | 0 |
| Retained Earnings | -996.0M | 135.8M | 2.2B | 2.2B | 1.6B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.9B | 3.0B | 5.0B | 4.9B | 1.9B |
| Key Metrics | |||||
| Total Debt | 2.8B | 2.7B | 2.6B | 2.8B | 139.3M |
| Working Capital | 481.2M | 220.1M | 476.7M | 568.1M | 1.1B |
Balance Sheet Composition
QuidelOrtho Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -1.1B | -2.1B | -10.1M | 548.7M | 704.2M |
| Depreciation & Amortization | 442.0M | 453.4M | 457.2M | 283.6M | 52.7M |
| Stock-Based Compensation | 45.9M | 42.1M | 51.6M | 48.4M | 25.4M |
| Working Capital Changes | -133.8M | -174.7M | -54.5M | -18.4M | 72.2M |
| Operating Cash Flow | -770.5M | -1.8B | 430.3M | 845.9M | 913.8M |
| Investing Activities | |||||
| Capital Expenditures | -188.2M | -195.1M | -209.3M | -140.9M | -292.8M |
| Acquisitions | - | 0 | 0 | -1.5B | 0 |
| Investment Purchases | 0 | -7.2M | -60.1M | -63.7M | -67.4M |
| Investment Sales | 0 | 63.1M | 78.3M | 53.4M | 3.8M |
| Investing Cash Flow | -192.7M | -149.9M | -187.6M | -1.6B | -319.5M |
| Financing Activities | |||||
| Share Repurchases | 0 | 0 | -7.2M | -74.3M | -103.5M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 2.6B | 198.0M | 0 | 2.7B | 0 |
| Debt Repayment | -2.4B | -143.0M | -228.0M | -2.4B | -300.0K |
| Financing Cash Flow | 155.8M | 48.8M | -265.8M | 252.0M | -173.1M |
| Free Cash Flow | -83.0M | -112.1M | 70.9M | 744.4M | 513.1M |
| Net Change in Cash | -807.4M | -1.9B | -23.1M | -546.3M | 421.2M |
Cash Flow Trend
QuidelOrtho Key Financial Ratios
Valuation Ratios
Forward P/E
4.15
Price to Book
0.42
Price to Sales
0.30
PEG Ratio
4.15
Profitability Ratios
Profit Margin
-41.46%
Operating Margin
4.01%
Return on Equity
-46.15%
Return on Assets
1.27%
Financial Health
Current Ratio
1.50
Debt to Equity
148.60
Beta
0.92
Per Share Data
EPS (TTM)
$-16.69
Book Value per Share
$28.28
Revenue per Share
$40.27
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| QDEL | 765.2M | - | 0.42 | -46.15% | -41.46% | 148.60 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Axogen | 1.9B | -110.18 | 13.15 | -13.49% | -6.97% | 55.50 |
| Establishment Labs | 1.9B | -37.89 | 79.68 | -133.25% | -24.19% | 1,123.15 |
| Artivion | 1.8B | 179.71 | 4.03 | 2.70% | 2.21% | 57.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.






